• 1. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 2. Alt-proteins: A promising future
• 3. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 4. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 5. An Assessment of the Laminar Hypersonic Double-Cone Experiments in the LENS-XX Tunnel
  JaideepRay,PatrickBlonigan,EricT.Phipps,KathrynMaupin

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives Naphthoylindoles

Professional Introduction to Compound with CAS No. 1427325-66-3 and Product Name: JWH-081 N-(5-Hydroxypentyl)

JWH-081 N-(5-Hydroxypentyl), a compound identified by the CAS number 1427325-66-3, represents a significant area of interest in the field of medicinal chemistry and pharmacology. This compound belongs to a class of synthetic cannabinoids that have garnered considerable attention due to their unique pharmacological properties and potential applications in research. The structure of JWH-081 N-(5-Hydroxypentyl) incorporates a hydroxypentyl side chain, which contributes to its distinct interaction profile with cannabinoid receptors, making it a subject of extensive study in understanding the mechanisms of action within the endocannabinoid system.

The endocannabinoid system (ECS) is a complex cell-signaling system present in humans and other mammals that plays a role in regulating various functions including appetite, pain sensation, mood, and memory. The ECS is composed of endocannabinoids, which are molecules produced naturally by the body, cannabinoid receptors (CB1 and CB2), and enzymes that regulate endocannabinoid levels. Synthetic cannabinoids like JWH-081 N-(5-Hydroxypentyl) are designed to mimic the effects of endocannabinoids by binding to these receptors, thereby modulating ECS activity. This has led to their exploration for potential therapeutic applications, as well as for understanding the pathophysiology of various disorders.

Recent research has focused on elucidating the pharmacokinetic and pharmacodynamic properties of JWH-081 N-(5-Hydroxypentyl). Studies have demonstrated that this compound exhibits potent binding affinity for both CB1 and CB2 receptors, though its selectivity profile may vary compared to other synthetic cannabinoids. The hydroxypentyl moiety in its structure appears to influence its metabolic stability and receptor interaction dynamics, which are critical factors in determining its overall efficacy and safety profile. These findings are particularly relevant in the context of developing novel therapeutic agents targeting ECS-related disorders.

One of the most compelling aspects of JWH-081 N-(5-Hydroxypentyl) is its potential in preclinical models for addressing conditions such as chronic pain, inflammation, and neurodegenerative diseases. Preclinical studies have shown that this compound can modulate pain signaling pathways and exhibit anti-inflammatory effects by interacting with CB1 and CB2 receptors. Additionally, its ability to cross the blood-brain barrier suggests that it may have central nervous system effects, which could be beneficial in treating neurological disorders. However, it is essential to note that while preclinical results are promising, further research is necessary to fully understand its clinical potential and any potential adverse effects.

The synthesis and characterization of JWH-081 N-(5-Hydroxypentyl) have been subjects of detailed investigation in synthetic organic chemistry. The introduction of the hydroxypentyl group into the molecular framework requires precise synthetic methodologies to ensure high yield and purity. Advanced techniques such as palladium-catalyzed cross-coupling reactions have been employed to construct the core scaffold of this compound efficiently. These synthetic approaches not only contribute to the availability of JWH-081 N-(5-Hydroxypentyl) for research purposes but also provide valuable insights into developing similar compounds with optimized properties.

In terms of analytical characterization, JWH-081 N-(5-Hydroxypentyl) has been extensively analyzed using various spectroscopic techniques including nuclear magnetic resonance (NMR), mass spectrometry (MS), and infrared spectroscopy (IR). These analytical methods are crucial for confirming the structural integrity of the compound and for studying its interactions with biological targets. High-resolution NMR spectroscopy has been particularly useful in determining the exact chemical environment of each atom within the molecule, providing detailed structural information that is essential for understanding its pharmacological behavior.

The growing interest in synthetic cannabinoids like JWH-081 N-(5-Hydroxypentyl) has also prompted regulatory bodies to monitor their development closely. While these compounds are not classified as controlled substances in all jurisdictions, their potential for misuse and unknown long-term effects necessitate careful consideration in both research and clinical settings. Ethical guidelines emphasize the importance of conducting thorough toxicological assessments before moving from preclinical to clinical phases. This ensures that any potential risks are identified early on, thereby safeguarding human health while advancing scientific knowledge.

Future directions in research involving JWH-081 N-(5-Hydroxypentyl) include exploring its potential as a lead compound for drug development. By modifying its chemical structure based on insights gained from preclinical studies, researchers aim to enhance its therapeutic index—improving efficacy while minimizing side effects. Additionally, investigating its interactions with other biological pathways may reveal novel applications beyond traditional ECS-related disorders. Collaborative efforts between chemists, pharmacologists, and clinicians will be crucial in translating these findings into tangible therapeutic benefits.

The impact of compounds like JWH-081 N-(5-Hydroxypentyl) extends beyond basic scientific discovery; they serve as valuable tools for understanding complex biological systems at a molecular level. By studying their effects on cannabinoid receptors and related signaling pathways, researchers can gain insights into disease mechanisms that might otherwise remain obscure. This knowledge is instrumental in developing targeted therapies that address specific pathological processes more effectively than broad-spectrum treatments.

In conclusion,JWH-081 N-(5-Hydroxypentyl) (CAS No. 1427325-66-3) represents a significant advancement in medicinal chemistry with implications for both research and potential therapeutic applications. Its unique structural features contribute to its distinct pharmacological profile, making it a compelling subject for further investigation within the endocannabinoid system framework. As research progresses，the full therapeutic potential c?a this compound will continue to unfold，offering hope for innovative treatments across multiple medical disciplines.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)